3 ms·
This is a wildly uninformed view. They do raise prices in Europe. And what happens? The government says “no” so patients don’t get access. Or the companies
by refurb 3y ago
This is a wildly uninformed view.
They do raise prices in Europe. And what happens? The government says “no” so patients don’t get access.
Or the companies just don’t launch the drug at all.
https://www.pmlive.com/pharma_news/bms_will_not_launch_cancer_drug_opdualag_in_germany_due_to_pricing_pressures_1489095 https://www.pmlive.com/pharma_news/bms_will_not_launch_cance...
Bristol Myers Squibb (BMS) has decided against launching its cancer drug Opdualag (nivolumab and relatlimab) in Germany due to pricing pressures.
- silverquiet 3y agoOh I was just curious about the logistics of raising prices in Europe in order to lower them in the US; as you say, it doesn't seem so simple. I wonder, how much does this Opdualag cost and how much benefit does it provide? My naive reading of your article seems that it adds an average of 3 months to the average patient's life? Here the math is quite simple but grim - how much would you pay for 3 more months of life?